Molecular Determinants for Activation of Human Ether-à-go-go-related Gene 1 Potassium Channels by 3-Nitro-N-(4-phenoxyphenyl) Benzamide

Vivek Garg, Anna Stary-Weinzinger, Frank Sachse, and Michael C. Sanguinetti

Department of Physiology (V.G., M.C.S.), Nora Eccles Harrison Cardiovascular Research & Training Institute (V.G., F.S., M.C.S.), and Department of Bioengineering (F.S.), University of Utah, Salt Lake City, Utah; and Department of Pharmacology and Toxicology, University of Vienna, Vienna, Austria (A.S.-W.)

Received June 2, 2011; accepted July 8, 2011

ABSTRACT

Human ether-à-go-go-related gene 1 (hERG1) channels mediate repolarization of cardiac action potentials. Inherited long QT syndrome (LQTS) caused by block of hERG1 channels as a toxic side effect of several commonly used medications (Sanguinetti and Tristani-Firouzi, 2006). Inherited loss-of-function mutations in hERG1 are a novel pharmacological approach to treat LQTS. 3-Nitro-n-(4-phenoxyphenyl) benzamide [ICA-105574 (ICA)] has been discovered to activate hERG1 by strong attenuation of pore-type inactivation. Here, we used scanning mutagenesis of hERG1 to identify the molecular determinants of ICA action. Three mutations abolished the activator effects of 30 μM ICA, including L622C in the pore helix, F557L in the S5 segment, and Y652A in the S6 segment. One mutation in S6 (A653M) switched the activity of ICA from an activator to an inhibitor, revealing its partial agonist activity. This was confirmed by showing that the nonactivating mutant hERG1 channel (G628C/S631C) was inhibited by ICA and that the addition of the F557L mutation rendered the channel drug-insensitive. Simulated molecular docking of ICA to homology models of hERG1 corroborated the scanning mutagenesis findings. Together, our findings indicate that ICA is a mixed agonist of hERG1 channels. Activation or inhibition of currents is mediated by the same or overlapping binding site located in the pore module between two adjacent subunits of the homotetrameric channel.

Introduction

The rapid delayed rectifier K+ current (I_{Kr}) conducted by human ether-à-go-go-related gene 1 (hERG1) channels is the predominant repolarizing current of cardiac action potentials in large mammals (Sanguinetti et al., 1995; Trudeau et al., 1995). Slow activation/deactivation and rapid inactivation of hERG1 channels leads to a peak in I_{Kr}, during phase 3 repolarization and thus is a critical regulator of action potential duration and heart rate (Sanguinetti and Tristani-Firouzi, 2006). Prolonged QT duration and TdP is most commonly an acquired disorder, often caused by block of hERG1 channels as a toxic side effect of several commonly used medications (Sanguinetti and Tristani-Firouzi, 2006). Individuals with either inherited or acquired LQTS are at an increased risk of cardiac arrhythmia and sudden death.

Congenital LQTS is commonly treated by administration of a β-adrenergic receptor blocker, and invasive and costly implantable defibrillators are used for the most severe cases. The available options for short-term drug-induced TdP are intravenous Mg^{2+}, correction of any electrolyte disturbance, and discontin-
ulation of the culprit drug. These options are inadequate for many patients and a mechanistic-based approach such as enhancing the cardiac repolarizing currents $I_{Ks}$ or $I_{KC}$ has been proposed (Goldenberg and Moss, 2008). Several compounds that activate hERG1 channels have been fortuitously discovered during routine off-target screening for channel block (Kang et al., 2005; Zhou et al., 2005; Hansen et al., 2006; Gerlach et al., 2010). The mechanisms of action of hERG1 activators include suppression of pore (P)-type inactivation and slowed deactivation. The putative binding site for two hERG1 activators, (3R,4R)-4-(3-(6-methoxyquinolin-4-yl)-3-oxo-propyl)-1-(3,2,5-trifluoro-phenyl)-prop-2-ynyl)-piperidine-3-carboxylic acid (RPR290243) (Kang et al., 2005) and 2-(4-[2-(3,4-dichloro-phenyl)-ethyl]-phenylamino)-benzoic acid (PD-118057) (Zhou et al., 2005), were described recently. The binding sites are distinct and can intuitively explain the predominant mechanism of action of each specific activator. RPR260243 binds near the intracellular gate of the channel (and close to S4–S5 linker) and markedly slows deactivation while also affecting inactivation by an undefined allosteric mechanism (Perry et al., 2007). PD-118057 binds to a pocket formed by the pore helix of one subunit and nearby S6 residues of an adjacent subunit to modestly attenuate P-type inactivation and increase single channel open probability ($P_o$) with only minor effects on deactivation (Perry et al., 2009).

Another activator of hERG1, 3-nitro-N-(4-phenoxypyphenyl) benzamide (ICA-105574) was reported to shorten action potential duration of isolated guinea pig cardiomyocytes in a concentration-dependent manner (Gerlach et al., 2010). At the maximally effective concentration, ICA induced a +180 mV shift in the voltage half-point ($V_{1/2}$) of inactivation, resulting in an increased outward current of 10 to 15 times the basal amplitude at 0 mV and slowed the rate of hERG1 current deactivation by 2-fold (Gerlach et al., 2010). To elucidate the molecular determinants for the effects of ICA, we used scanning mutagenesis of the pore region of hERG1, expression of mutant channels in Xenopus laevis oocytes and voltage clamp for functional analysis of mutant channels and determined the effects of ICA on inactivation-impaired hERG1 mutant channels.

**Materials and Methods**

**Channel Mutagenesis and Expression in X. laevis Oocytes.** hERG1 (KCNH2, isoform 1a), was cloned into the pSP64 oocyte expression vector, and mutations were introduced using the QuickChange mutagenesis kit (Agilent Technologies, Santa Clara, CA). Residues Leu553 to Ile656 in S6, Thr618 to Ser624 in PH, and Cys643 to Ile663 in S6 were mutated to alanine or cysteine (to glycine or valine for alanine residues). For some residues, alternate substitutions were introduced to enhance expression (F557L, L622C, Y652A, and A653M) of hERG1. Mutants F557L, L622C, Y652A, and A653M of hERG1 were expressed in PyMOL (http://www.pymol.org/). MD simulations of closed models were performed with Gromacs version 4.5.4 (http://www.gromacs.org/) (Hess et al., 2008). Wild-type (WT) and mutant channels were embedded in an equilibrated simulation box of palmitoyloleyl phosphatidylcholine lipids. Lipid parameters were taken from Berger et al. (1997), and the OPLS-all-atom force field (Jorgensen et al., 1996) was used for the protein. The solvent was described by the TIP4P water model (Jorgensen et al., 1983). Electrostatic interactions were calculated explicitly at a distance <1 nm, long-range electrostatic interactions were calculated at every step by particle-mesh Ewald summation (Darden et al., 1993). Lenard-Jones interactions were calculated with a cutoff of 1 nm. All bonds were constrained by using the LINCS algorithm (Hess et al., 1997), allowing for an integration time step of 2 fs. The Nose-Hoover thermostat (Nose, 1984) was used for temperature coupling ($\tau = 0.1$ ps) and the Parrinello-Rahman barostat algorithm (Parrinello and Rahman, 1981) for pressure coupling. Conjugate gradient energy-minimization steps (1000) were performed, followed by 2 ns of re-
strained MD, in which the protein atoms were restrained with a force constant of 1000 kJ/mol·nm⁻² to their initial position, whereas ions, lipids, and solvent were allowed to move freely. Each system was then subjected to 2 × 10 ns of unrestrained MD, during which coordinates were saved every 1 ps for analysis.

Coordinates of ICA105574 were generated with GaussView 5, and the geometry was optimized with the Hartee-Fock 3–21G basis set implemented in Gaussian 09 (Gaussian Inc., Wallingford, CT) (Frisch et al., 2009). Docking was performed with the program Gold 4.0.1 (Jones et al., 1995). Coordinates of the geometric center calculated among residues Phe557, Leu622, Tyr652, and Ala653 were taken as binding site origin. The binding site radius was set equal to 10 Å. Operations (150,000) of the GOLD genetic algorithm were used to dock the selected compounds into the WT and mutant channels. Three snapshots (3, 6, and 8 ns) were taken from MD trajectories. The Chemscore scoring function was used to estimate free energies of binding (Gold.Chemscore.DG). Reported values are averaged over the 10 best docking poses.

**Solutions and Drugs.** For two-microelectrode voltage-clamp experiments, the extracellular solution contained the following: 98 mM NaCl, 2 mM KCl, 1 mM CaCl₂, 1 mM MgCl₂, and 5 mM HEPES, pH 7.6. ICA was purchased from Sigma-Aldrich (St. Louis, MO). Drug solutions were prepared fresh just before experiment by dilution of a 10 mM DMSO stock solution of ICA. Each oocyte was treated with a single concentration (30 μM) of drug unless specified otherwise.

**Results**

ICA Increases hERG1 Current by Suppressing Inactivation But Has No Effect on Single-Channel Conductance, Maximal Conductance, or Gating Currents. The effects of 10 and 30 μM ICA on WT hERG1 channels expressed in *X. laevis* oocytes are illustrated in Fig. 1, A and B. ICA induced a marked concentration-dependent enhancement of current magnitude. Activation of hERG1 current by 30 μM ICA reached a steady state in ~10 min at 30 μM. The fold increase in current assayed with 1-s pulses to a test potential (Vₜ) of +20 mV was 7.6 ± 1.1 at 10 μM and 28 ± 3.4 at 30 μM, (n = 3–8). The potency of ICA was reduced in

---

**Fig. 1.** Voltage-dependent activation of hERG1 current by ICA-105574 (ICA) in *X. laevis* oocytes. A, ICA increases the magnitude of hERG1 current. Currents were elicited with 1-s pulses to test potentials applied in 10-mV increments from −80 to +50 mV. Tail currents (Iₚ₋ₚ₋ₜ) were measured at −70 mV. Voltage protocol is shown above control current traces. B, I-Vt relationships measured before (control) and in presence of 10 and 30 μM ICA. Data were fitted with a Boltzmann function (smooth curves). For control, V₀.5 was also observed for vehicle (DMSO) control (see Supplemental Fig. 1).
oocytes compared with that reported (Gerlach et al., 2010) for human embryonic kidney 293 cells (EC<sub>50</sub> = 0.5 μM), probably because ICA is highly lipophilic (logP = 3.69) and accumulates in the yolk of oocytes (Witchel et al., 2002). The increase in current by ICA was associated with a marked decrease in rectification of the current-voltage (I-V) relationship (Fig. 1B) and an enhanced effect at more positive test potentials (Fig. 1C), effects consistent with a large drug-induced positive shift in the V<sub>0.5</sub> of inactivation as reported previously (Gerlach et al., 2010). ICA binds to the closed state of the hERG1 channel (Gerlach et al., 2010). In Fig. 1D, we show that ICA can also bind to channels when applied to an oocyte during a prolonged depolarizing step to +30 mV, indicating that the drug can also bind to channels in the open or inactivated state.

The voltage-dependence of the hERG1 channel conductance-voltage relationship was determined by measuring peak tail currents (I<sub>tail</sub>) after a 1-s depolarizing pulse to a variable V<sub>t</sub>. For these experiments, oocytes were bathed in 20 mM [K<sup>-</sup>]o solution to preclude variation in I<sub>tail</sub> magnitude caused by the transient local accumulation of extracellular K<sup>-</sup> and thus, chemical driving force associated with large outward currents and low [K<sup>-</sup>]o. When I<sub>tail</sub> values were elicited at −140 mV, a potential in which recovery from inactivation is rapid and complete, ICA did not alter the voltage-dependence or G<sub>max</sub> of the conductance-voltage relationship for hERG1 (Fig. 1E). This finding suggests that ICA does not cause any significant change in single-channel activity or induce recruitment of channels to the surface membrane. To confirm these expectations, we determined the effect of ICA on single-channel conductance and gating currents.

Single hERG1 channel activity was determined in cell-attached patches of oocytes using pipettes filled with 104 mM [K<sup>-</sup>]o solution (Supplemental Fig. 1). The slope conductance for single-channel activity was not altered when 30 μM ICA was included in the pipette and bath solution (Fig. 1F). Although unlikely, ICA might also increase current magnitude by recruiting channels from a cytoplasmic store to the plasma membrane. As an indirect measure of plasma-membrane bound channel density, we determined the maximum intramembrane charge displacement (Q<sub>OFF-max</sub>) associated with the OFF gating current. The cut-open oocyte voltage-clamp technique (Stefani and Bezanilla, 1998) was used to measure hERG1 gating currents. ICA had no effect on the kinetics of gating currents or the magnitude of the maximum intramembrane charge displacement (Q<sub>OFF-max</sub>) associated with the OFF gating current compared with currents treated with vehicle (DMSO) (Fig. 1G and Supplemental Fig. 1).

Together, these findings indicate that the ICA-induced increase in hERG1 current is not due to an increase in maximum whole-cell conductance, single-channel conductance, or an increased number of functional channels at the surface membrane and, thus, can be attributed solely to a marked attenuation of P-type inactivation (Gerlach et al., 2010).

To further explore the role of inactivation in the mechanism of action of ICA, its effects on three inactivation-impaired mutant hERG1 channels were determined (Fig. 2). S620T hERG1 channels have greatly reduced inactivation (Ficker et al., 1998) and, as expected, exhibited a greatly reduced response to ICA (only 1.3 ± 0.2-fold increase at +50 mV, n = 7). Two other point mutations (S631A, N588K) also attenuate hERG1 inactivation (Schoenherr and Heinemann, 1996; Brugada et al., 2004), albeit to a lesser extent than the S620T mutation, and as expected, these channels were more sensitive to the drug compared with S620T hERG1 channels (Fig. 2). At +50 mV, 30 μM ICA increased S631A channel currents by 3.2 ± 0.2-fold (n = 4) and N588K channel currents by 2.4 ± 0.1-fold (n = 3), far less that the 47-fold enhancement observed for WT hERG1 channels (Fig. 1C). Thus, current enhancement by ICA is strongly correlated with the extent of intrinsic P-type inactivation of hERG1 channels.

**Molecular Determinants for ICA Binding.** Based on mutational analysis of hERG1 (Ficker et al., 1998), the entire pore module, including the pore helix/selectivity filter (PH/SF), S5 and S6 segments participate in channel inactivation.

![Fig. 2](https://molpharm.aspetjournals.org/)

**Fig. 2.** Mutant channels with impaired inactivation are less sensitive to ICA. A, S620T hERG1 currents recorded before (control) and after 30 μM ICA (left and middle). Currents were elicited as described in Fig. 1A. Right, plots of mean I-V<sub>t</sub> relationships determined before (□) and after 30 μM ICA (○). Currents (I<sub>tail</sub>) were measured at the end of 1-s test pulses and normalized relative to the peak outward value of control currents (n = 7). B and C, current traces (left and middle) and I-V<sub>t</sub> relationships (right) for S631A (n = 4) and N558K (n = 3) hERG1 channels.

Based on previous studies (Ficker et al., 1998), the entire pore module, including the pore helix/selectivity filter (PH/SF), S5 and S6 segments participate in channel inactivation.
To determine the molecular determinants of ICA activity, we performed scanning mutagenesis of major portions of the hERG1 pore module (Fig. 3A). A total of 44 residues were mutated, including Leu553 to Ile567 in S5, Thr618 to Ser624 in the PH/SF, and Cys643 to Ile663 in S6. The effect of ICA (30 μM for 10 min) on individual mutant channels was quantified as the fold increase in outward current measured at the end of a 1-s pulse to a V3 of +20 mV (Fig. 3B).

Nine mutations attenuated the response to 30 μM ICA by ≥10-fold and were classified as “high-impact” residues (Fig. 3B). All of these mutant channels exhibited normal P-type inactivation as revealed by their typical bell-shaped I-V relationships. Three mutations prevented the activation of hERG1 by ICA. F557L and L622C channels were completely insensitive to 30 μM ICA (Fig. 4, A and B). ICA induced a slight but insignificant increase in outward Y652A channel currents and accelerated the rate of current deactivation; at −70 mV, the time constants for fast and slow phases of deactivation (τf and τs) were 99 ± 9.8 and 329 ± 36 ms for control, respectively, compared with 53 ± 8.3 and 221 ± 37 ms for 30 μM ICA (n = 6). Currents at +20 mV for five other mutant channels (F619A, S624A, F656T, N658A, and V659A) were increased <3-fold by 30 μM ICA (Supplemental Fig. 2). ICA inhibited one mutant hERG1 channel (A653M) and accelerated its rate of deactivation (Fig. 4D); at −70 mV, τf and τs were 60 ± 3.9 and 283 ± 25 ms, respectively, compared with 41 ± 3.7 and 216 ± 27 ms for drug (n = 6). In contrast to Y652A and A653M channels, ICA slowed the rate of monoexponential deactivation of WT channels at −70 mV by ~2-fold, from 413 ± 10 to 751 ± 62 ms (n = 6). Four mutant channels (T618A, T623A, M645C, and G648A) exhibited enhanced inactivation or very low expression and were therefore recorded in an extracellular solution containing 104 mM K+ to accentuate the magnitude of inward Itail. ICA enhanced T618A channel currents, but reduced T623A, M645C, and G648A channel currents by 30 to 50% (Supplemental Fig. 3). In summary, scanning mutagenesis identified three mutations (F557L, L622C, Y652A) that eliminated or attenuated the activator effects as well as four mutations (T623A, M645C, G648A, and A653M) that revealed an inhibitory activity of ICA.

Theoretically, the molecular determinants of channel activation by ICA overlap, but are not identical with other well characterized hERG1 activators, including RPR260243 (Phe557, Leu622, Tyr652, Asn658, and Val659) and PD-118057 (Phe619, Leu622, and Tyr652) that eliminated or attenuated the activator effects as well as four mutations (T623A, M645C, G648A, and A653M) that revealed an inhibitory activity of ICA.

Simulated Docking of ICA on hERG1. A homology model of the hERG1 pore module was constructed by using the KcsA (closed state) and KvAP (open state) channel structures as templates. ICA binds perpendicularly to the channel axis between two adjacent subunits of the pore module in both the open (Fig. 5A) and closed (Fig. 5C) states. A close-up view of the putative drug-binding region is depicted in Fig. 5B and D, in which the high-impact residues identified by scanning mutagenesis and a few other residues in close con-
A Single Residue in S5 of hERG1 Determines whether ICA Is an Activator or Inhibitor. We next determined the effects of ICA on a mutant hERG1 channel that does not inactivate. Combined mutation of two residues (G628C/S631C) located near or within the selectivity filter of hERG1 completely removes channel inactivation and reduces K⁺ selectivity (Smith et al., 1996). Currents conducted by G628C/S631C hERG1 channels were not augmented by ICA; instead, a 30 μM concentration of the drug decreased currents by 40% (Fig. 6, A and B). This reduction of current could result from drug binding to the central cavity receptor described for potent hERG1 blockers (Mitcheson et al., 2000). An important component of the blocker binding site is Tyr652, and mutations of this residue can greatly attenuate drug-induced block of WT channels. However, introduction of the Y652A mutation did not alter the response of G628C/S631C hERG1 channels to ICA (Fig. 6C), suggesting that current reduction is not caused by binding of ICA to the central cavity. Moreover, introduction of the F557L mutation (that prevents activator effects on WT channels) eliminated the response of G628C/S631C hERG1 channels to ICA (Fig. 6D). Together these findings suggest that ICA exerts its

mate free energies of binding (Gold.Chemscore.DG) of ICA and were averaged over the 10 best docking poses for WT and mutant channels. ΔG values were −40.9 and −40.54 kJ/mol for WT channels in the closed and open states, respectively, and were reduced in the closed state of the mutant channels as follows: −32.97 (F557L), −36.09 (L622C), −37.69 (Y652A), and −38.21 kJ/mol (A653M).

A Single Residue in S5 of hERG1 Determines whether ICA Is an Activator or Inhibitor. We next determined the effects of ICA on a mutant hERG1 channel that does not inactivate. Combined mutation of two residues (G628C/S631C) located near or within the selectivity filter of hERG1 completely removes channel inactivation and reduces K⁺ selectivity (Smith et al., 1996). Currents conducted by G628C/S631C hERG1 channels were not augmented by ICA; instead, a 30 μM concentration of the drug decreased currents by 40% (Fig. 6, A and B). This reduction of current could result from drug binding to the central cavity receptor described for potent hERG1 blockers (Mitcheson et al., 2000). An important component of the blocker binding site is Tyr652, and mutations of this residue can greatly attenuate drug-induced block of WT channels. However, introduction of the Y652A mutation did not alter the response of G628C/S631C hERG1 channels to ICA (Fig. 6C), suggesting that current reduction is not caused by binding of ICA to the central cavity. Moreover, introduction of the F557L mutation (that prevents activator effects on WT channels) eliminated the response of G628C/S631C hERG1 channels to ICA (Fig. 6D). Together these findings suggest that ICA exerts its

A Single Residue in S5 of hERG1 Determines whether ICA Is an Activator or Inhibitor. We next determined the effects of ICA on a mutant hERG1 channel that does not inactivate. Combined mutation of two residues (G628C/S631C) located near or within the selectivity filter of hERG1 completely removes channel inactivation and reduces K⁺ selectivity (Smith et al., 1996). Currents conducted by G628C/S631C hERG1 channels were not augmented by ICA; instead, a 30 μM concentration of the drug decreased currents by 40% (Fig. 6, A and B). This reduction of current could result from drug binding to the central cavity receptor described for potent hERG1 blockers (Mitcheson et al., 2000). An important component of the blocker binding site is Tyr652, and mutations of this residue can greatly attenuate drug-induced block of WT channels. However, introduction of the Y652A mutation did not alter the response of G628C/S631C hERG1 channels to ICA (Fig. 6C), suggesting that current reduction is not caused by binding of ICA to the central cavity. Moreover, introduction of the F557L mutation (that prevents activator effects on WT channels) eliminated the response of G628C/S631C hERG1 channels to ICA (Fig. 6D). Together these findings suggest that ICA exerts its

A Single Residue in S5 of hERG1 Determines whether ICA Is an Activator or Inhibitor. We next determined the effects of ICA on a mutant hERG1 channel that does not inactivate. Combined mutation of two residues (G628C/S631C) located near or within the selectivity filter of hERG1 completely removes channel inactivation and reduces K⁺ selectivity (Smith et al., 1996). Currents conducted by G628C/S631C hERG1 channels were not augmented by ICA; instead, a 30 μM concentration of the drug decreased currents by 40% (Fig. 6, A and B). This reduction of current could result from drug binding to the central cavity receptor described for potent hERG1 blockers (Mitcheson et al., 2000). An important component of the blocker binding site is Tyr652, and mutations of this residue can greatly attenuate drug-induced block of WT channels. However, introduction of the Y652A mutation did not alter the response of G628C/S631C hERG1 channels to ICA (Fig. 6C), suggesting that current reduction is not caused by binding of ICA to the central cavity. Moreover, introduction of the F557L mutation (that prevents activator effects on WT channels) eliminated the response of G628C/S631C hERG1 channels to ICA (Fig. 6D). Together these findings suggest that ICA exerts its

A Single Residue in S5 of hERG1 Determines whether ICA Is an Activator or Inhibitor. We next determined the effects of ICA on a mutant hERG1 channel that does not inactivate. Combined mutation of two residues (G628C/S631C) located near or within the selectivity filter of hERG1 completely removes channel inactivation and reduces K⁺ selectivity (Smith et al., 1996). Currents conducted by G628C/S631C hERG1 channels were not augmented by ICA; instead, a 30 μM concentration of the drug decreased currents by 40% (Fig. 6, A and B). This reduction of current could result from drug binding to the central cavity receptor described for potent hERG1 blockers (Mitcheson et al., 2000). An important component of the blocker binding site is Tyr652, and mutations of this residue can greatly attenuate drug-induced block of WT channels. However, introduction of the Y652A mutation did not alter the response of G628C/S631C hERG1 channels to ICA (Fig. 6C), suggesting that current reduction is not caused by binding of ICA to the central cavity. Moreover, introduction of the F557L mutation (that prevents activator effects on WT channels) eliminated the response of G628C/S631C hERG1 channels to ICA (Fig. 6D). Together these findings suggest that ICA exerts its
agonist and antagonist effects by binding to a single or overlapping receptor site.

Discussion

Activation of hERG1 channels by ICA is state-independent and mediated by a pronounced positive shift in the voltage dependence of P-type inactivation (Gerlach et al., 2010). P-type inactivation is caused by very subtle changes in the dynamic structure of the selectivity filter (Cuello et al., 2010b). Mutation of residues located within or near the PH/SF that impaired inactivation (S620T, S631A) caused reduced sensitivity to the drug. Inhibition of a mutant channel (G628C/S631C hERG1) with inactivation removed (Smith et al., 1996) revealed that ICA also has intrinsic antagonist activity. Phe557 (S5) and Leu622 (PH) are considered to be the most critical determinants of the binding site because single mutations of either residue prevented drug-induced changes in current magnitude and kinetics.

Voltage-gated channels can be considered analogous to intrinsically active receptors that are modulated by voltage. Viewed in this manner, ICA can behave as either an agonist or an inverse agonist of hERG1 channels. The drug is an agonist (i.e., activator) when bound to WT hERG1 channels and an inverse agonist (i.e., inhibitor) when bound to A653M or G628C/S631C hERG1 channels. Strictly speaking, the term inverse agonist would apply only if ICA bound to the same site to mediate both activator and inhibitory effects. Inhibition of noninactivating mutant hERG1 channels could simply result from pore block, mediated by binding of ICA to the central cavity as described for a plethora of hERG1 blockers (Mitcheson et al., 2000; Sanguinetti and Mitcheson, 2005) and distinct from the proposed activator site. Alternatively, both activation and inhibition of channel activity by ICA could arise from its binding to a single site as proposed for dihydropyridines that can either activate or inhibit L-type Ca\(^{2+}\) channels (Hockerman et al., 1997). For several reasons, we favor the hypothesis that ICA binds to a single site in both WT or mutant channels, and that current inhibition results from stabilization of channels in a closed (or inactivated) state rather than pore blockage per se. First, the putative activator site described for WT channels should remain intact in G628C/S631C hERG1 channels; lack of drug effect on F557L/G628C/S631C hERG1 channels supports this view. Second, if ICA bound to the well characterized central cavity site (Mitcheson et al., 2000), mutation of Tyr652 or Phe656 in hERG1 would be expected to cause an enhanced activator response rather than the observed diminished response. The side chains of these aromatic residues are the most important molecular determinants of many hERG1 blockers (Sanguinetti and Mitcheson, 2005). Mutation of Phe66 to threonine enhanced the activator effect of 1,3-bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643) compared with WT channels (Casis et al., 2006), consistent with two binding sites for these lipophilic compounds alter channel gating and are proposed to gain direct access to the pore module via the lipid membrane.

Mutation of Tyr652 to alanine prevents the attenuation of inactivation normally caused by RPR260243 (Perry et al., 2007). However, deactivation of Y652A hERG1 channels is markedly slowed by RPR260243 (Perry et al., 2007), indicating that the mutation does not prevent drug binding. Y652A channels are also resistant to the normally pronounced effect of ICA on inactivation. However, opposite to the effects on WT channels, deactivation of Y652A channels was accelerated by ICA. The ability of both ICA and RPR260243 to affect deactivation but not inactivation of Y652A channels suggests that Tyr652 residues are required for coupling drug binding to suppression of channel inactivation. Modeling suggests that Tyr652 directly interacts with ICA but not with RPR260243 (Perry et al., 2007). Based on sequence alignments of S6 segments, Tyr652 is equivalent to Phe103 of KcsA and Ile470 of Shaker K+ channels. Mutation of Phe103 (KcsA channel) or Ile470 (Shaker channel) drastically suppresses C-type inactivation, and Cuello et al. (2010a) have proposed that these key residues in S6 allosterically couple the cytosolic gate with the extracellular gate (selectivity filter), so-called bidirectional coupling. In contrast, mutations of Tyr652 in hERG1 do not appreciably alter inactivation gating (Fernandez et al., 2004). The mechanism responsible for disrupted coupling between drug binding and altered inactivation of Y652A hERG1 channels requires further study.

In summary, ICA binds to a hydrophobic pocket located between two adjacent hERG1 channel subunits, resulting in a subtle change in configuration of the selectivity filter that disrupts inactivation gating. Binding of ICA to the same or overlapping site mediates inhibition of mutant A653M and G628C/S631C hERG1 channels.

Acknowledgments

We thank Jennifer Abbruzzese for measurement of gating currents, Tobias Linder and Kirsten Knape for help with modeling figures, and Kam Hoe Ng for isolation and injection of oocytes.
Authorship Contributions

Participated in research design: Garg and Sanguinetti.
Conducted experiments: Garg and Sanguinetti.
Performed data analysis: Garg, Stary-Weininger, Sachse, and Sanguinetti.

Wrote or contributed to the writing of the manuscript: Garg, Stary-Weininger, and Sanguinetti.

References


